Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone678-270-3631
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30,000.00
Profitability
Miscellaneous
Employees50
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions
What is Clearside Biomedical's stock symbol?
Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."
How were Clearside Biomedical's earnings last quarter?
Clearside Biomedical Inc (NASDAQ:CLSD) issued its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.09. The business had revenue of $0.05 million for the quarter. View Clearside Biomedical's Earnings History.
When is Clearside Biomedical's next earnings date?
What price target have analysts set for CLSD?
8 brokerages have issued 12 month target prices for Clearside Biomedical's stock. Their predictions range from $4.00 to $29.00. On average, they anticipate Clearside Biomedical's stock price to reach $11.8333 in the next year. This suggests a possible upside of 894.4% from the stock's current price. View Analyst Price Targets for Clearside Biomedical.
What is the consensus analysts' recommendation for Clearside Biomedical?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clearside Biomedical.
Has Clearside Biomedical been receiving favorable news coverage?
Press coverage about CLSD stock has been trending somewhat positive on Thursday, InfoTrie reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Clearside Biomedical earned a coverage optimism score of 1.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Clearside Biomedical's key competitors?
Some companies that are related to Clearside Biomedical include Nature's Sunshine Products (NATR), BELLUS Health (BLUSF), Chimerix (CMRX), Ardelyx (ARDX), Axovant Gene Therapies (AXGT), BioXcel Therapeutics (BTAI), TAIWAN LIPOSOME/S (TLC), Evofem Biosciences (EVFM), Applied Therapeutics (APLT), Intec Pharma (NTEC), Menlo Therapeutics (MNLO), REDHILL BIOPHAR/S (RDHL), Newron Pharmaceuticals (NWPHF), Strongbridge Biopharma (SBBP) and Checkpoint Therapeutics (CKPT).
What other stocks do shareholders of Clearside Biomedical own?
Who are Clearside Biomedical's key executives?
Clearside Biomedical's management team includes the folowing people:
- Dr. George M. Lasezkay Pharma.D., J.D., Interim CEO & Director (Age 67)
- Mr. Charles A. Deignan, Chief Financial Officer (Age 55)
- Mr. Stephen C. Kilmer, Investor Relations Officer (Age 53)
- Mr. Leslie B. Zacks, Gen. Counsel, Chief Compliance Officer & Sec. (Age 50)
- Mr. Rick McElheny, VP of Corp. Devel.
When did Clearside Biomedical IPO?
(CLSD) raised $50 million in an IPO on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.
Who are Clearside Biomedical's major shareholders?
Clearside Biomedical's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.91%), Virtu Financial LLC (0.19%), Wellington Management Group LLP (0.17%), Parallel Advisors LLC (0.17%), SG Americas Securities LLC (0.16%) and California State Teachers Retirement System (0.11%). Company insiders that own Clearside Biomedical stock include Charles A Deignan, Christy L Shaffer, Clay Thorp, Daniel H White and Gerald D Cagle. View Institutional Ownership Trends for Clearside Biomedical.
Which institutional investors are selling Clearside Biomedical stock?
CLSD stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Renaissance Technologies LLC, BlackRock Inc., JPMorgan Chase & Co. and California State Teachers Retirement System. View Insider Buying and Selling for Clearside Biomedical.
Which institutional investors are buying Clearside Biomedical stock?
CLSD stock was purchased by a variety of institutional investors in the last quarter, including Parallel Advisors LLC, SG Americas Securities LLC, Virtu Financial LLC and State of Wisconsin Investment Board. Company insiders that have bought Clearside Biomedical stock in the last two years include Charles A Deignan, Christy L Shaffer, Clay Thorp, Daniel H White and Gerald D Cagle. View Insider Buying and Selling for Clearside Biomedical.
How do I buy shares of Clearside Biomedical?
Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clearside Biomedical's stock price today?
One share of CLSD stock can currently be purchased for approximately $1.19.
How big of a company is Clearside Biomedical?
Clearside Biomedical has a market capitalization of $44.74 million and generates $30,000.00 in revenue each year. The company earns $-82,820,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Clearside Biomedical employs 50 workers across the globe.
What is Clearside Biomedical's official website?
How can I contact Clearside Biomedical?
Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]
MarketBeat Community Rating for Clearside Biomedical (NASDAQ CLSD)
MarketBeat's community ratings are surveys of what our community members think about Clearside Biomedical and other stocks. Vote "Outperform" if you believe CLSD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSD will underperform the S&P 500 over the long term. You may vote once every thirty days.
